Darb-Esfanhani and colleagues also demonstrated through immunohistochemical analysis of ISG15 expression on 128 high grade serous ovarian cancer that patients with ISG15-positive tumors had a significantly longer overall survival than patients with ISG15-negative tumors. Here, ISG15 is linked to ovarian serous adenocarcinoma.